Rapid Direct Determination of Low and High Molecular Weight Kininogen in Human Plasma by Particle Concentration Fluorescence Immunoassay (PCFIA)

Summary

In this study, we employed Particle Concentration Fluorescence Immunoassay (PCFIA), for directly measuring both high and low molecular weight kininogens (HK and LK) in human plasma. In 38 normal donors, the mean values for plasma kininogens were 93 mg/ml +/- 19 SD, 82 mg/ml +/- 12 SD, and 175 mg/ml +/- 29 SD, respectively for LK, HK, and TotK (the sum of LK and HK detected by their common heavy chains). Plasma completely deficient in HK and LK was unreactive (<0.25 mg/ml) in all 3 assays whereas plasma from a patient with Fitzgerald Trait had an HK value of 11 mg/ml, an LK value of 36 mg/ml and a TotK value of 59 mg/ml. The reagents can be prepared in advance and all three kininogen determinations can be performed, using the same diluted sample, on 24 plasma samples, in triplicate, or 40 plasma samples, in duplicate, in less than 1 h. By performing all 3 kininogen determinations, it is possible to differentiate cleaved from intact kininogens. This technique will facilitate the widespread screening of kininogen levels in biological fluids of normal humans as well as of patients with various diseases.

• References

• 1 Jacobsen S. Separation of two different substrates for plasma kinin-forming enzymes. Nature 1966; 210: 98-99
• 2 Jacobsen S, Kriz M. Some data on two purified kininogens from human plasma. Br J Pharmacol Chemother 1967; 29: 25-36
• 3 Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakamishi S. Structure organization of the kininogen gene and a model for its evolution. J Biol Chem 1985; 260: 8610-8617
• 4 Sueyoshi T, Enjyoji K, Kato H, Iwanaga S, Bando Y, Kominami E, Katunuma N. A new function of kininogens as thiol proteinase inhibitors: inhibition of papain and cathepsins B, H, and L by bovine, rat, and human kininogens. FEBS Lett 1985; 182: 193-195
• 5 Puri RN, Zhou F, Hu CJ, Colman RF, Colman RW. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-507
• 6 Margolis J, Bishop EA. Studies on plasma kinins. 1. The composition of kininogen complex. Austral J Exp Biol 1963; 41: 293-306
• 7 Schiffman S, Lee P. Partial purification and characterization of contact activation cofactor. J Clin Invest 1975; 56: 1082-1092
• 8 Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman Factor. Proc Natl Acad Sci USA 1976; 73: 2554-2558
• 9 Mandle Jr R, Colman RW, Kaplan AP. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-4183
• 10 Thompson RE, Mandle Jr R, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-1380
• 11 Lottspeich F, Kellermann A, Henschen A, Rauth G, Müller-Esterl W. Human low molecular mass kininogen. Amino acid sequence of the light chain; homology with other protein sequences. Eur J Biochem 1984; 142: 227-232
• 12 Pierce JV, Guimaraes JA. Further characterization of highly purified human plasma kininogens. In: Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease. Pisano JJ, Austen KF. eds DHEW Pub No 76-791. 1974. p 121-127
• 13 Nakajima T, Hirsch EF, Oshima G, Herman CM, Erdos EG. Kallikrein-kinin system responses in septic shock in men and baboons. In: Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease. Pisano JJ, Austen KF. eds DHEW Pub No 76-791. 541-544 1967
• 14 Sakamoto W, Fukuda H, Nishikaze O. Kininogen and kallikrein in saliva of periodontally-diseased subjects. J Dent Res 1981; 60: 6-9
• 15 Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis Jr LJ, Curd JG, Colman RW. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983; 308: 1050-1053
• 16 Colman RW, Edelman R, Scott CF, Gilman RH. Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978; 61: 287-296
• 17 Proud D, Togias A, Naclerio RM, Crush SA, Norman PS, Lichtenstein LM. Kinins are generated in vivo followed nasal airway challenge of allergic individuals with allergen. J Clin Invest 1983; 72: 1678-1685
• 18 Baumgartner CR, Togias AG, Naclerio RM, Lichtenstein PS, Proud D. Influx of kininogens into nasal secretions after antigen challenge of allergic rhinitis. J Clin Invest 1985; 76: 191-197
• 19 Brenner M, Baumgartner C, Kunkel G, Rudolf R, Kirchof E. The possible role of bradykinin as a mediator of bronchial asthma. Allergol Immunopathol 1982; 10: 453-462
• 20 Abe K, Wantanabe N, Kumagai N, Mouri T, Yoshinaga K. Circulating plasma kinin in patients with bronchial asthma. Experientia 1967; 23: 626-627
• 21 Worthy K, Figueroa CD, Dieppe PA, Bhoola KD. Kallikreins and kinins: mediators in inflammatory joint disease?. Int J Exp Pathol 1990; 71: 587-601
• 22 Berretinni M, Laemmle B, White T, Heeb MJ, Schwarz HP, Zuraw B, Curd J, Griffin JH. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68: 455-462
• 23 Laemmle B, Berrettini M, Griffin JH. Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen. Sem Thromb Hemost 1987; 13: 106-114
• 24 Laemmle B, Zuraw BL, Heeb MJ, Schwarz HP, Berretini M, Curd JG, Griffin JH. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. Thromb Haemost 1988; 59: 151-161
• 25 Schmaier AH, Farber A, Schein R, Sprung C. Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. J Lab Clin Med 1988; 112: 182-192
• 26 Buhler R, Hovinga JK, Aebi-Huber I, Furlan M, Laemmle B. Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47 kDa light chain. Blood Coag & Fib 1995; 06: 223-232
• 27 Reddigari S, Kaplan AP. Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody. JImmMeth 1989; 119: 19-25
• 28 Vogel R, Assfalg-Machleidt I, Esterl A, Machleidt W, Müller-Esterl W. Proteinase-sensitive regions in the heavy chain of low molecular weight kininogen map to the inter-domain junctions. J Biol Chem 1988; 263: 12661-12668
• 29 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-1662
• 30 Scott CF, Pixley RA, Colman RW. A new assay for high molecular weight kininogen in human plasma using a chromogenic substrate. Thromb Res 1987; 48: 685-700
• 31 Proud D, Pierce JV, Pisano JJ. Radioimmunoassay of high molecular weight kininogen in normal and deficient plasmas. J Lab Clin Med 1980; 95: 563-574
• 32 Syvanen A-C, Turpeinen U, Siimesmaa S, Hamberg U. A radioimmunoassay for the detection of molecular forms of human plasma kininogen. FEBS Letters 1981; 129: 241-245
• 33 Bouma BN Kerbiriou DM, Vlooswijk RAAGriffinJH. Immunochemical studies of prekallikrein, kallikrein, and high molecular weight kininogen in normal and deficient plasma and in normal plasma following cold dependent activation. J Lab Clin Med 1980; 96: 693-709
• 34 Kerbiriou-Nabias DM, Garcia FO, Larrieu M-J. Radioimmunoassays of human high and low molecular weight kininogens in plasmas and platelets. BrJ Haematol 1984; 56: 273-286
• 35 van IwaardenF, de GrootPG, Sixma JJ, Berrettini MB, Bouma BN. High-molecular weight kininogen is present in cultured human endothelial cells: Localization, isolation, and characterization. Blood 1988; 71: 1268-1276
• 36 Scott CF, Colman RW. Sensitive antigenic determinations of high molecular weight kininogen performed by covalent coupling of capture antibody. J Lab Clin Med 1992; 119: 77-86
• 37 Legris F, Martel-Pelletier J, Pelletier J-P, Colman R, Adam A. An ultrasensitive chemiluminoenzyme immunoassay for the quantification of human tissue kininogens: application to synovial membrane and cartilage. J Immunol Meth 1994; 168: 111-121
• 38 Scott CF, Silver LD, Schapira M, Colman RW. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest 1984; 73: 954-962
• 39 Kleniewski J, Dingle S, Donaldson V. Comparison of properties of monoclonal and polyclonal antibodies against the light chain of human high molecular weight kininogen. J Lab Clin Med 1988; 111: 93-103
• 40 Scott CF, Whitaker EJ, Hammond BF, Colman RW. Purification and characterization of a potent 70 kDa thiol lysyl-proteinase (lys-gingivain) from P. gingivalis that cleaves kininogens and fibrinogen. J Biol Chem 1993; 268: 7935-7942
• 41 Scott CF, Silver LD, Purdon AD, Colman RW. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem 1985; 260: 10856-10863
• 42 Uchida Y, Katori M. An improved method for determination of the total kininogen in rabbit and human plasma. Biochem Pharmacol 1978; 27: 1463-1469
• 43 Uchida Y, Katori M. Differential assay for high molecular weight kininogen and low molecular weight kininogen. Thromb Res 1979; 15: 127-134
• 44 Henderson L, Figueroa CD, Miiller-Esterl W, Bhoola KD. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 1994; 84: 474-482
• 45 Adam A, Albert A, Calay G, Coosset J, Damas J, Franchimont P. Human kininogens of Low and High Molecular Mass: Quantification by Radioimmunoassay and determination of reference values. Clin Chem 1985; 31: 423-426
• 46 Jerabek I, Stetina Z, Furtner R, Binder BR, Maier M. Determination of human low molecular weight kininogen by immunoassay. Agents Actions-Supplements 1992; 38: 257-266
• 47 Jolley ME. Principles of particle concentration fluorescence immunoassay. Baxter, Pandex Division Research Report Number 1. 1983
• 48 Engvall E, Perlman P. Enzyme-linked immunoassay (ELISA): Quantitative assay of immunoglobulin G. Immunochemistry 1971; 08: 871-874
• 49 Kaufmann J, Haasemann M, Modrow S, Müller-Esterl W. Structural dissection of the multidomain kininogens. J Biol Chem 1993; 268: 9079-9091
• 50 Schmaier AH, Schutsky D, Farber A, Silver LD, Bradford HN, Colman RW. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 1987; 262: 1405-1411
• 51 Johnson DA, Salvesen G, Brown MA, Barrett AJ. Rapid isolation of human kininogens. Thromb Res 1987; 48: 187-193
• 52 Hasan AK, Cines DB, Zhang J, Schmaier AH. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem 1994; 269: 31822-31830
• 53 Müller-Esterl W. Kininogens. In: “Methods Of Enzymatic Analysis, 3^rd edition,”. Vol. “Proteins and Peptides”. Hubergmeyer W. ed. 09. VCH Weinheim; Germany: 1986
• 54 Burnette WN. “Western Blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodifed nitrocellulose and radiographic detection with antibody and radiolabeled Protein A. Anal Biochem 112: 195-203
• 55 Reddigari S, Kaplan AP. Cleavage of human high molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 1988; 71: 1334-1340
• 56 Saito H, Ratnoff OD, Waldmann R, Abraham JP. Fitzgerald Trait: Deficiency of a hitherto unrecognized agent, Fitzgerald Factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability (PF/DIL). J Clin Invest 1975; 55: 1082-1089
• 57 DeLa CadenaRA, Bradford HN, Kunapuli SP, Colman RW. The platelet binding site on the heavy chain of human high (HK) and low (LK) molecular weight kininogen is confined to residues Lys-262-Pro-272. Thromb Haemost 1993; 69: 781 (Abst # 854)
• 58 Vroman L, Adams AL. Identification of rapid changes at plasma-solid phase interfaces. J Biomed Mater Res 1969; 03: 43-47
• 59 Schmaier AH, Silver L, Adams AL, Fisher GC, Munoz PC, Vroman L, Colman RW. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 1984; 33: 51-67
• 60 Brash JL, Scott CF, ten HoveP, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 1988; 71: 932-939